
Anti-VEGF therapy not as harmful as previously thought
Anti-VEGF therapy doesn?t not significantly affect visual acuity and metamorphopsia in patients treated for retinal pigment epithelium tears in eyes, according to a paper featured in Retina.
Anti-VEGF therapy doesn’t not significantly affect visual acuity and metamorphopsia in patients treated for retinal pigment epithelium tears in eyes, according to a paper featured in Retina.
A team led by Dr C.A. Moreira Jr, Hospital de Olhos do Parana and Department of Ophthalmology, Universidade Federal do Parana, Curitiba, Brazil, conducted a retrospective study on five patients with retinal pigment epithelial tears after anti-VEGF injections.
Macular findings were obtained by angiography and optical coherence tomography. An anti-VEGF drug was re-injected until the membranes ceased leaking.
Mean visual acuity after the tear was 20/160 and final visual acuity was 20/60. The amount of anti-VEGF ire-injections varied from two to eight during the follow-up period. Reduced fluid and remodelling of the torn retinal pigment epithelium was demonstrated by the results of the OCT analysis.
The long-term results with repeated anti-VEGF are not as damaging and previously suggested in similar studies. Visual acuity and metamorphopsia improve over time if the neovascular membrane is inactive.
To read the abstract please click




















